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A B S T R A C T
The kidney plays an important role in maintaining the systemic Ca2+ and Mg2+ balance. Thus the
renal reabsorptive capacity of these cations can be amended to adapt to disturbances in plasma
Ca2+ and Mg2+ concentrations. The reabsorption of Ca2+ and Mg2+ is driven by transport of other
electrolytes, sometimes through selective channels and often supported by hormonal stimuli. It
is, therefore, not surprising that monogenic disorders affecting such renal processes may impose
a shift in, or even completely blunt, the reabsorptive capacity of these divalent cations within
the kidney. Accordingly, in Dent’s disease, a disorder with defective proximal tubular transport,
hypercalciuria is frequently observed. Dysfunctional thick ascending limb transport in Bartter’s
syndrome, familial hypomagnesaemia with hypercalciuria and nephrocalcinosis, and diseases
associated with Ca2+-sensing receptor defects, markedly change tubular transport of Ca2+ and
Mg2+. In the distal convolutions, several proteins involved in Mg2+ transport have been identified
[TRPM6 (transient receptor potential melastatin 6), proEGF (pro-epidermal growth factor) and
FXYD2 (Na+/K+-ATPase γ -subunit)]. In addition, conditions such as Gitelman’s syndrome,
distal renal tubular acidosis and pseudohypoaldosteronism type II, as well as a mitochondrial
defect associated with hypomagnesaemia, all change the renal handling of divalent cations. These
hereditary disorders have, in many cases, substantially increased our understanding of the complex
transport processes in the kidney and their contribution to the regulation of overall Ca2+ and Mg2+
balance.
INTRODUCTION
Divalent cations are essential for physiological processes,
such as intracellular signalling, enzyme activation, neural
excitability, muscle contraction and bone formation.
Overall Ca2+ balance is regulated via a co-ordinated
interplay between the parathyroid glands, bone,
intestine and kidneys. Systemic Mg2+ concentrations are
Key words: divalent cation, kidney, hereditary disorder, reabsorption, tubular transport.
Abbreviations: BP, blood pressure; BSND, Bartter’s syndrome with sensorineural deafness; CaSR, Ca2+-sensing receptor;
CD, collecting duct; CLC, Cl− channel; CNT, connecting tubule; DCT, distal convoluted tubule; dRTA, distal renal tubular
acidosis; EGF, epidermal growth factor; EGFR, EGF receptor; ENaC, epithelial Na+ channel; FHH, familial hypocalciuric
hypercalcaemia; FHHNC, familial hypomagnesaemia with hypercalciuria and nephrocalcinosis; FXYD2, Na+/K+-ATPase
γ -subunit; GFR, glomerular filtration rate; HSH, hypomagnesaemia with secondary hypocalcaemia; IRH, isolated autosomal-
recessive hypomagnesaemia; NCC, Na+–Cl− co-transporter; NHE3, Na+/H+ exhanger 3; NKCC2, furosemide-sensitive Na+–
K+–2Cl− co-transporter; NSHPT, neonatal severe primary hyperparathyroidism; OCRL, oculocerebrorenal syndrome of Lowe;
PCT, proximal convoluted tubule; PHAII, pseudohypoaldosteronism type II; PST, proximal straight tubule; PTH, parathyroid
hormone; ROMK, renal outer medullary K+ channel; TAL, thick ascending limb; TRP, transient receptor potential; TRPM, TRP
melastin; TRPV, TRP vanilloid; WNK kinase, with-no-lysine kinase; ZO-1, zona occludens-1.
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Figure 1 Schematic representation of the nephron listing the predominant origins of intrarenal transport defects causing
dysfunctional renal handling of divalent cations
In most species, the transition from the DCT to the CNT is gradual, whereas the transition between these nephron segments in the rabbit is very abrupt. In species
where these borders are less well defined with larger segments containing DCT and CNT cells intermingled, the occurrence of the CNT cell is often considered the start
of CNT segment [108]. In addition to the CNT cells, intercalated cells involved in acid/base secretion also arise in this segment [108]. Note that defects causing PHAII
probably originate from both the DCT and CNT segments, whereas dRTA is caused by distrubed acid/base handling in intercalated cells of the CNT and CD regions.
iCD, initial CD; PT, proximal tubules.
maintained in a similar manner; however, the exact
mechanisms governing plasma Mg2+ concentrations are
less well defined. As essential cellular functions are re-
liant on maintaining extracellular Ca2+ and Mg2+ concen-
trations within a narrow range, the consequences of
disturbances in these divalent cations often result in
symptoms related to instability of the neurological
and cardiac systems. Hence hypercalcaemia can lead
to fatigue, nausea, coma and abnormal heart rhythms
that can result in cardiac arrest [1]. Hypocalcaemia can
produce tetany, carpopedal spasms and life-threatening
arrhythmias [2]. Hypermagnesaemia also causes severe
symptoms, including lethargy, coma and cardiac arrest
[3]. Similarly, hypomagnesaemia promotes neuromuscu-
lar irritability, such as tetany and seizures, as well as
cardiac arrhythmias. Secondary hypocalcaemia is also
commonly observed in patients with hypomagnesaemia,
further complicating their condition [3].
The kidney plays a central role in controlling the
excretion of Ca2+ and Mg2+ in response to conditions of
deprivation or excess of these cations [4,5]. Transepithelial
(i.e. net result of paracellular and transcellular) transport
of divalent cations across the epithelia differs in the
various nephron segments. Accordingly, the proximal
tubule and TAL (thick ascending limb) reabsorb these
ions in a passive paracellular manner, whereas in the
distal convolutions active transcellular transport occurs.
Many inherited renal diseases related to electrolyte and
even protein transport cause defects in the handling
of Ca2+ and Mg2+ by the kidney (Figure 1). The
aim of the present review is to summarize the current
knowledge pertaining to these diseases and how they have
contributed to our understanding of renal divalent cation
handling.
PROXIMAL TUBULES
Plasma free/ionized Ca2+ levels are maintained within a
narrow range around the set-point value of 1.2 mmol/l [6].
Approx. 50–60 % of total plasma Ca2+ is freely diffusible,
the majority as ionized Ca2+, the remaining complexed
to other ions. This free portion of the total Ca2+ is
filtered by the glomeruli. The remainder is bound to
plasma proteins, predominantly albumin, and is largely
retained in plasma [7–9]. Of the filtered Ca2+, only
1–2 % is excreted by the kidney, the largest fraction
being reclaimed by the renal tubules [7,9]. Detailed
micropuncture studies have estimated that approx. 55–
60 % of the filtered Ca2+ is re-absorbed along the PCT
(proximal convoluted tubule). An additional 10 % is
reabsorbed in the PST (proximal straight tubule) [10–13].
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Ca2+ reabsorption in the PCT occurs in proportion to
Na+ and water. Hence proximal tubular Ca2+ transport
is thought to be primarily passive in nature [14].
The tubule fluid/filterable plasma Ca2+ ratio has been
reported to range from 1.0 to 1.2 along the PCT [11,15].
Thus the isotonic removal of Na+ and water from
the lumen increases the intraluminal Ca+ concentration
and facilitates secondary Ca2+ reabsorption [11,12]. This
is in line with the existence of a paracellular shunt
pathway, where the electrochemical gradient across the
epithelia sets the direction of transport. Importantly,
volume expansion (probably by reducing proximal Na+
and water reabsorption and, hence, the electrochemical
driving force for Ca2+) has been demonstrated to reduce
proximal tubular Ca2+ reabsorption, whereas volume
contraction increases the proximal tubular reabsorptive
capacity [16].
The systemic Mg2+ concentration is maintained
between 0.75 and 1.0 mmol/l [17]. Approx. 70 % of Mg2+
in serum is freely filterable, either existing as ionized free
Mg2+ or complexed with filterable anions [18]. Thus the
concentration of Mg2+ reached in the initial glomerular
filtrate is approx. 0.5 mmol/l [8,19]. The kidney excretes
approx. 3–5 % of the Mg2+ found in the ultrafiltrate [20].
Although the PCT has a high permeability to Na+ and
Ca2+, as well as a high tubular reabsorptive capacity
for these ions, a limited amount of Mg2+ (approx. 10–
20 %) is reabsorbed in this nephron segment [15,19,21].
Similar permeability properties have been reported for the
PST [22]. Thus the entire proximal tubule is responsible
for reclaiming some 25 % of the filtered Mg2+. The
short half-life of the radioactive 28Mg2+ isotope makes
it unsuitable as a tracer and has seriously hampered
the experimental determination of Mg2+ fluxes and
permeability coefficients. Hence most determinations
of Mg2+ in tubular punctates have been performed
using electron probes, limiting the determinations to
net Mg2+ fluxes. Under these experimental settings,
proximal tubular Mg2+ transport is generally thought to
be paracellular. Owing to the apparent permeability dif-
ferences, Na+-driven water transport increases the intra-
luminal concentration of Mg2+ along the proximal tubu-
lar epithelium [22,23]. It has been determined that a
tubule fluid/filterable Mg2+ ratio of 1.9 is necessary for
Mg2+ reabsorption to occur in the segment [15]. This
suggests that adequate water removal is a prerequisite
for Mg2+ transport to occur and may, therefore, only
commence in the late PCT, when the luminal Mg2+
concentration is sufficiently high [15]. Moreover, the
high concentration gradient necessary for transepithelial
Mg2+ transport suggests a poor permeability of the tight
junctions to Mg2+ in the proximal tubule. Interestingly,
the proximal reabsorptive capacity in the neonatal rat
is much higher, as reabsorption of filtered Mg2+ ranges
between 60 and 70 % [24]. Whether this represents a
remodelling of the selectivity filter in the tight junction
protein complex during development remains unclear. In
contrast with Ca2+, volume expansion does not appear to
affect proximal tubular Mg2+ reabsorption [25].
TRANSPORT DEFECTS OF THE PROXIMAL
TUBULE AFFECTING DIVALENT
CATION HANDLING
Dent’s disease
Dent’s disease is a recessive X-linked proximal tubular
disorder associated with low-molecular-mass protein-
uria. Males usually present with a more severe
phenotype, including aminoaciduria, hypercalciuria,
nephrolithiasis, glycosuria and progressive renal failure
[26–28]. Individuals with Dent’s disease typically have
normal plasma Mg2+ concentrations. Some patients
present with rickets, which is normalized after
pharmacological 1,25-dihydroxyvitamin D3 treatment
[26]. In general, patients with Dent’s disease have mildly
elevated 1,25-dihydroxyvitamin D3 levels [26,29]. Thus
1,25-dihydroxyvitamin D3 may serve to stabilize plasma
Ca2+ levels secondary to renal Ca2+ wasting or elevated
1,25-dihydroxyvitamin D3 levels may by itself augment
the hypercalciuria [29].
Dent’s disease is caused by mutations in the CLC5
gene [28]. CLC5, originally identified as a Cl− channel, is
also known to function as a lysosomal Cl−/H+ antiporter
involved in endosomal acidification [30,31]. CLC5 local-
izes to the proximal tubule, the TAL and the CD (col-
lecting duct) intercalated cells [32]. Genetic ablation of
Clc5 in mice impairs proximal tubular endocytosis
of proteins by inhibiting the trafficking of megalin and
cubilin [33–35], largely explaining the low-molecular-
mass proteinuria. Similarly, aminoaciduria and glycosuria
may occur due to defective trafficking of the transport
proteins responsible for proximal tubular reabsorption
of these solutes [36]. It is important to note that two
different mice strains have been generated with a targeted
deletion of Clc5 [34,35]. Although many of the renal
phenotypic characteristics observed in Dent’s disease are
present in both mice, important differences are observed
in terms of hypercalciuria, 1,25-dihydroxyvitamin D3
levels, nephrocalcinosis and renal failure (reviewed in
detail in [37]). Thus, currently, the exact underlying
mechanism responsible for hypercalciuria remains to be
clarified.
Interestingly, a kidney-specific deletion of megalin
(Lrp2) in mice causes hypocalcaemic hypercalciuria,
vitamin D deficiency and extrarenal symptoms such
as rickets [38,39]. The inactive vitamin D precursor
25-dihydroxyvitamin D3, complexed to the vitamin
D-binding proteins, has been shown to be reabsorbed in
the proximal tubules by the endocytic receptor megalin
[39]. Thus megalin-mediated uptake of inactive 25-di-
hydroxyvitamin D3 by the proximal tubule appears a
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Figure 2 Schematic representation of the cellular composition of renal ion and water transport proteins within the various
nephron segments
The iCD (intial CD) represents the start of the CD principal cells arising in the late distal convolutions. The CNT and the iCD principal cells express TRPV5, as
does NCC-expressing cells in the DCT2 segment in many species [118–121]. The DCT cell portrayed in the Figure resembles one located in the early DCT region.
Transepithelial voltages are listed for the PT [204], TAL [55,56], although the transepithelial voltage may increase to approx. + 30 mV [57–59], DCT [55,10,111] and
CNT [109]. AQP, aquaporin; PTHR, PTH receptor; ATP6B1 (ATP6V1B1), B1 subunit of H+ ATPase; ATP6N1B (ATP6V0A4), 116 kDa subunit a isoform 4 of H+ ATPase;
PT, proximal tubules.
prerequisite for conversion into its active form 1,25-
dihydroxyvitamin D3. However, it is currently unknown
whether this mechanism contributes to hypercalciuria
in Dent’s disease, as impaired uptake is not reflected in
the serum 1,25-dihydroxyvitamin D3 concentrations.
Whether ablation of the transporter in more distal
segments promotes hypercalciuria remains untested.
OCRL (oculocerebrorenal syndrome
of Lowe)
OCRL is an X-linked disease caused by mutations
in OCRL1, which encodes an inositol polyphosphate
5-phosphatase [40]. Affected males have congenital catar-
acts, mental retardation and renal tubular dysfunction.
Evidence suggests that OCRL1 protein deficiency can
impair lysosomal trafficking in the proximal tubule via
accumulation of the substrate phosphatidylinositol 4,5-
bisphosphate [41,42]. Thus, similar to Dent’s disease,
massive low-molecular-mass proteinuria as well as other
characteristics of proximal tubular dysfunction are
observed. Additionally, renal tubular acidosis is often
detected in patients with Lowe’s syndrome. Individuals
suffering from the syndrome only infrequently display
normocalcaemic hypercalciuria and calcifications [43].
Strikingly, patients have also been identified with
mutations in OCRL1 that develop an isolated renal
Dent’s disease-like phenotype with hypercalciuria, but
without tubular acidosis and extrarenal symptoms, such
as cataracts and neurological abnormalities [44]. It is
currently unknown how mutations in a single gene can
cause two supposedly distinct phenotypes.
TAL
Micropuncture experiments have demonstrated that
approx. 20–25 % of the filtered Ca2+ and 60 % of filtered
Mg2+ is reabsorbed in the TAL [10,11,45]. In this
segment, the transport of divalent cations occurs in a
passive paracellular manner. In most species, the cortical
TAL appears to be most important for paracellular
transport, as medullary transport is negligible under basal
conditions [46–49]. The lumen-positive transepithelial
voltage appears to be the most important driving force
for Ca2+ and Mg2+ reabsorption. Furosemide, a potent
inhibitor of Na+, K+ and Cl− co-transport, almost
completely abolishes the transepithelial voltage gradient
across the TAL [50–52]. Under these conditions, Ca2+ and
Mg2+ transport is drastically inhibited [53,54]. As shown
in Figure 2, NKCC2 (furosemide-sensitive Na+–K+–
2Cl− co-transporter) serves as the apical entry mechanism
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for Na+, K+ and Cl− in the TAL. Similarly, ROMK2
(renal outer medullary K+ channel 2) is necessary for
apical K+ recycling across the apical membrane. Inwardly
transported Cl− exits across the basolateral mem-
brane, predominantly via CLC-Kb channels. The Na+/
K+-ATPase constitutes the initial driving force for
Na+ transport in the TAL. Other transporters involved
in vectorial Na+ transport have also been identified
[i.e. NHE3 (Na+/H+ exhanger 3)] in the medullary
TAL. However, their exact contribution to overall Na+
transport within the loop is unclear.
The generation of a lumen-positive transepithelial
voltage drives the paracellular reabsorption of Ca2+ and
Mg2+ from the lumen. The electric gradient is likely to be
made up of two mechanisms. NKCC2-mediated uptake
of Na+, K+ and two Cl− ions coupled with the subsequent
secretion of K+ across the apical membrane generates
a lumen-positive voltage of approx. 5–10 mV [55,56].
Secondly, reabsorption of Na+ along the length of the
TAL reduces the intraluminal Na+ concentration. Under
these conditions, backflux of Na+ from the interstitium to
the tubular lumen may further augment voltage to values
of approx. 30 mV [57–60].
cAMP-elevating hormones such as PTH (parathyroid
hormone) stimulate Na+/Cl− transport in the TAL, prob-
ably by modulating these transport processes [49,61].
Interestingly, after application of PTH, changes in net
Ca2+ and Mg2+ transport appear much higher than
the concomitant changes reported in the transepithelial
voltage. These observations suggest that alterations
in the permeability of the paracellular pathway can
modulate transepithelial divalent cation transport [61].
Similarly, CaSR (Ca2+-sensing receptor) is expressed in
the basolateral membrane of the TAL, where it modulates
transport in response to changes in extracellular divalent
cations [62,63]. Here activation of CaSR can inhibit
vasopressin-induced cAMP formation by as much as
90 % [64]. Conversely, in vitro microperfusion experi-
ments have shown that activation of the receptor inhibits
net transport of Ca2+, while leaving the transepithelial
voltage and net Na+/Cl− flux intact [64,65]. However,
chronic stimulation of the receptor is likely to reduce
NKCC2 abundance as its expression is stimulated by
cAMP. This is observed in rats administered genta-
mycin, an aminoglycoside antibiotic that activates CaSR
[66,67]. In contrast, some reports have suggested that
pharmacological inhibition of transepithelial voltage does
not substantially affect Ca2+ transport in the TAL, which
is suggestive of a transcellular pathway [48,65,68]. The
nature of this transcellular route remains poorly defined,
although it can presently not be excluded. Why only
20–25 % of the filtered Ca2+ is reabsorbed in the TAL,
whereas as much as 60 % of filtered Mg2+, is not entirely
clear, but may represent differences in either delivery of
divalent cations to the bend of Henle’s loop or permea-
bility differences for divalent cations within the TAL.
TRANSPORT DEFECTS OF THE TAL
AFFECTING DIVALENT CATION HANDLING
Bartter’s syndrome
Bartter’s syndrome is characterized by severe renal
Na+/Cl− wasting, hypokalaemic metabolic alkalosis,
hyperreninaemia, hyperaldosteronism and prostaglandin
E2 hypersecretion, and patients present with a normo-
or hypo-tensive phenotype [69–71]. Most gene defects
causing Bartter’s syndrome are inherited in an autosomal-
recessive manner. Mutations in the genes encoding
NKCC2 (SLC12A1) or ROMK (KCNJ1) lead to
antenatal Bartter’s syndrome [72,73]. Defects in either
protein severely impair transport function in the TAL,
produce renal Na+/Cl− wasting and dilute the interstitial
gradient, resulting in a pronounced urinary concentrating
defect. Thus antenatal Bartter’s syndrome is the most
severe form of Bartter’s syndrome, being evident pre-
natally with polyhydramnios and often premature
birth. Post-natally, severe polyuria causes volume
depletion/dehydration and fever. Marked hypercalciuria,
secondary nephrocalcinosis and osteopenia are hallmark
features of antenatal Bartter’s syndrome [71]. Inter-
estingly, hypermagnesuria and hypomagnesaemia are
not common characteristics of this type of Bartter’s
syndrome. CLC-Kb is a basolateral Cl− channel located
in the TAL, as well as more distal nephron segments
[74]. In comparison with the apical entry and recycling
mechanisms, CLC-Kb appears not to be the sole efflux
pathway for Cl− in the TAL. Accordingly, the K+–Cl−
co-transporter and potentially other Cl− channels located
in the TAL may participate in removing intracellular Cl−
[75,76]. As suggested by Konrad et al. [75], the level of
compensation provided by these efflux pathways may
explain why the clinical definition is highly variable in
patients with recessive CLCNKB (the gene encoding
CLC-Kb) defects [75]. Thus individuals with CLC-K
dysfunction and, hence, classical Bartter’s syndrome
can present with an antenatal Bartter’s-syndrome-like
phenotype to being almost asymptomatic [75,77]. In
contrast with patients with antenatal Bartter’s syndrome,
hypercalciuria and nephrocalcinosis are an uncommon
feature in these individuals; however, hypomagnesaemia
occurs in up to 50 % of affected individuals [75,77].
Recessive mutations in BSND (Bartter’s syndrome with
sensorineural deafness; encoding Barttin, a β-subunit
necessary for CLC-Kb function) lead to perhaps the
most severe form of antenatal Bartter’s syndrome,
with sensorineural deafness and associated chronic renal
failure [78,79]. In line with this, defects in both CLC-
Ka and CLC-Kb confer a phenotype identical with that
reported for BSND Barttin) mutations [80]. In contrast
with CLC-Kb defects, mutations in BSND do not result
in hypomagnesaemia. The absence of renal Mg2+ wasting
has been attributed to the low GFR (glomerular filtration
rate) often observed in BSND, paralleling the decline in
C© The Authors Journal compilation C© 2010 Biochemical Society
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renal function. Nephrocalcinosis is not a common feature
of this disease [81].
Autosomal-dominant hypocalcaemic hypercalciuria is
observed in patients with activating mutations in CASR
(the gene encoding CaSR) [82,83]. Patients generally
present with mild asymptomatic hypocalcaemia, and
with serum Mg2+ and PTH levels in the lower-to-
normal range [82]. Functional analysis of these mutant
receptors revealed a left-shift in the dose–response curve;
thus lower Ca2+ concentrations increase half-maximal
activity of the receptor [82,83]. Some activating mutations
appear to be more severe in changing the responses
to extracellular Ca2+ and, thus, lead to an autosomal-
dominant form of Bartter’s syndrome [62,83,84]. These
patients present with a phenotype similar to classical
Bartter’s syndrome, but with hypocalcaemia, suppressed
secretion of PTH, renal Ca2+ wasting and nephrocalc-
inosis. Hypomagnesaemia and hypermagnesuria have
also been reported in these patients [62,84].
It is interesting to note that, although all of the Bartter’s
syndrome types described are caused by inhibition
of TAL transport and full or partial dissipation of
the electrochemical gradient, there is a considerable
variability in the consequence for the handling of divalent
cations. Several theories have been presented to explain
this diversity; however, the exact reasons for these
controversies still remain largely enigmatic. Less Na+ loss
is reported in most patients with Bartter’s syndrome with
CLC-Kb defects (in comparison with antenatal Bartter’s
syndrome), which often show a less severe phenotype
and also a decreased prevalence of hypercalciuria and
secondary nephrocalcinosis. It is difficult to directly
envision the electrochemical gradients for Mg2+ and
Ca2+ in the TAL of patients with Bartter’s syndrome,
as both volume depletion and polyuria will affect
both systemic and tubular concentrations, and probably
provoke compensatory mechanisms. However, it is prob-
able that renal Na+ wasting is less severe in patients
with Bartter’s syndrome with CLC-Kb defects and,
therefore, that the lumen-positive voltage is less affected.
This may explain why these patients rarely present with
hypercalciuria compared with individuals with antenatal
Bartter’s syndrome. Unfortunately, no clear correlation
between urinary Na+ and Ca+ wasting has been presented
in individuals with Bartter’s syndrome. Thus addi-
tional phenotypic characterization of factors affecting
Ca2+ wasting in Bartter’s syndrome might elucidate
this.
Why the opposite relationship is observed for renal
Mg2+ handling between the Bartter’s syndromes is also
unclear. The low prevalence of hypermagnesuria in
antenatal Bartter’s syndrome suggests an enormous com-
pensatory capacity of the DCT (distal convoluted tubule).
In addition, patients with mutations in CLCNKB have a
higher prevalence of hypermagnesuria. The expression of
CLC-Kb has been reported to be the highest in the DCT
[74]. Some patients with CLCNKB mutations present
with a mixed Bartter’s syndrome/Gitelman’s syndrome
phenotype with hypomagnesaemia [85]. Hence loss of
CLC-Kb in segments distal to the TAL may contribute
to this phenotype. The potential mechanism whereby this
occurs is not known.
FHHNC (familial hypomagnesaemia with
hypercalciuria and nephrocalcinosis)
Patients with the autosomal-recessive disorder FHHNC
often develop severe hypomagnesaemia, due to a
grossly increased fractional renal excretion of Mg2+.
Similarly, affected individuals have hypercalciuria,
although systemic concentrations of Ca2+ are within the
normal range [86,87]. Bilateral nephrocalcinosis is obser-
ved in all patients, and the severity of this finding is
correlated with the progression of renal insufficiency.
Ultimately, this leads to chronic renal failure. The
primary problem is renal in origin, which is supported
by the observation that affected individuals after renal
transplantation normalize their plasma Mg2+ concen-
trations and return to a normocalciuric state
[87].
Originally identified by Simon et al. [88], a defect
in CLDN16, the gene encoding the tight junction
protein claudin-16 (also known as paracellin-1), is
now known to be the underlying cause of FHHNC
[88]. Initial hydrophobic cluster analysis indicated that
claudin-16 forms four transmembrane domains with
intracellular C- and N-termini. The protein was found
to localize to the tight junctions of the TAL, as well
as the DCT [88–90], suggesting a possible role for
claudin-16 in regulating the paracellular permeability to
divalent cations. The mutations described often encode a
single amino acid substitution in the transmembrane or
extracellular domains of claudin-16, probably rendering
the protein non-functional [88,91]. Another mutation in
CLDN16 has been reported, which confers a less severe
phenotype with regression of the hypercalciuria and
maintenance of the GFR. The mutation, which is found
within a putative PDZ domain, appears predominantly
to prevent the binding of claudin-16 to ZO-1 (zona
occludens-1) and causes mislocalization of the protein
to lysosomes [92]. Although the regulation of claudin-
16 remains incompletely understood, phosphorylation of
claudin-16 at Ser217 via the cAMP/PKA (protein kinase
A) pathway appears to confer regulation by localizing
claudin-16 to the tight junctions [93]. This is to some
degree compatible with the observation that the cAMP-
elevating hormone PTH can change the permeability of
the paracellular pathway to Ca2+ and Mg2+ [61].
Individuals with a similar phenotype to patients
with mutations in CLDN16 have been described
[89]. Affected individuals had severe hypomagne-
saemia due to renal Mg2+ losses, in addition
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to bilateral nephrocalcinosis and renal insufficiency.
The disease in these individuals was complic-
ated by severe ocular problems, contrasting with infre-
quent milder ocular problems observed in patients
with CLDN16 mutations. Patients were found to have
mutations in the CLDN19 gene, which encodes claudin-
19 in the same family of tight junction proteins.
Complete co-localization with claudin-16 was found
within the kidney [89], implicating a role in divalent ion
homoeostasis.
Expressing claudin-16 in cells has generated highly
variable results in terms of cation permeability (reviewed
by [94]). When claudin-16 is expressed in LLC-PK1 cells,
a high permeability for Na+ is observed, while the Cl−
flux remains unaffected. Moreover, the permeability for
Mg2+ was much smaller than that observed for Na+
[59]. In the same cells, claudin-19 expression decreased
absolute permeability to Cl−, without affecting the Na+
permeability [95]. When co-expressed, the tight junction
becomes selective for cations [95]. This is in line with
studies reporting a paracellular shunt pathway for Na+
in the cortical TAL that is cation selective [57,96].
Expression of FHHNC-causing mutants of claudin-16
reduced selectivity for cations in LLC-PK1 cells [59].
Similarly, mutations in claudin-19 decreased its ability to
block Cl− permeation, leaving Na+ permeability intact
[95]. It remains unclear whether Mg2+ even permeates
these claudins in sufficient degree to support the massive
reabsorptive capacity for this ion in the TAL [59,94].
Using RNA interference, depletion of claudin-16 in mice
also confers an FHHNC-like phenotype. Interestingly,
microperfusion studies demonstrated that these mice
have a 50 % reduction in the paracellular cation selectivity
of the TAL (PNa/PCl) [97]. Furthermore, no change in the
selectivity between Na+ and Mg2+ was found (PNa/PMg),
suggesting that claudin-16 functions predominantly as a
non-selective cation channel [97].
How can changes in paracellular Na+ fluxes explain
the aetiology of FHHNC? On the basis of studies by
Hou, Goodenough and co-workers [59,95], it is suggested
that mutations in claudin-16 or claudin-19 in FHHNC
would increase the permeability of the tight junction
to anions, promote backflux of proportionally more
Cl−, and thereby dissipate the transepithelial voltage
gradient. One would also expect some sort of Na+/Cl−
wasting to occur in the TAL; however, patients with
FHHNC due to a defective CLDN16 gene retain
their ability to conserve urinary Na+ after Na+/Cl−
deprivation, have normal aldosterone levels and have
appropriate natriuretic responses to furosemide. Yet, their
calciuretic and magnesiuretic response to furosemide is
severely blunted [98]. Conversely, in theCldn16-depleted
mice, lowered BP (blood pressure), an increase in the
urinary Na+/K+ ratio and elevated aldosterone levels
are observed, along with enhanced CD Na+ transport
[97,99].
Familial benign hypercalcaemia and
NSHPT (neonatal severe primary
hyperparathyroidism)
Inactivating mutations in CASR have been identi-
fied in hypercalcaemic patients with FHH (familial
hypocalciuric hypercalcaemia) and a severe neonatal
form of primary hyperparathyroidism (NSHPT).
Although FHH is inherited in an autosomal-
dominant fashion, NSHPT is caused by homozyg-
ous inactivating mutations in CASR. Patients with
FHH can have hypercalcaemia and hypermagne-
saemia, while an inappropriate reduction in urinary
Ca2+ excretion is observed. A lower renal excretion
of Mg2+ has also been reported in FHH [100].
Moreover, serum PTH concentrations are often found
within the normal range, in the presence of hyper-
calcaemia, or even elevated levels have been reported in
a subset of patients [101]. Thus inactivating mutations
in the CASR allele shifts the set point of Ca2+ in this
condition, blunting the normal ability to reduce PTH
secretion in response to elevated Ca2+ levels and by
directly increasing renal Ca2+ and Mg2+ reabsorption
[63,102–104]. Although patients with FHH can have
lifelong hypercalcaemia and hypermagnesaemia, they are
generally asymptomatic [104]. In NSHPT, homozygous
inactivation of the CASR gene cause infantile hyperpara-
thyroidism. This rare disorder is life-threatening, with
severe hypocalciuric hypercalcaemia. Many extrarenal
symptoms associated with hypercalcaemia are observed.
In addition, polyuria and dehydration is commonly
reported [63,105]. Renal hyperabsorption of divalent
cations is partly caused by increased PTH levels, resulting
from reduced suppression of PTH secretion in the
CaSR-impaired parathyroid. In addition, an intrinsic
mechanism due to reduced functionality or an absence of
CaSR in the TAL occurs independently of PTH [106].
This becomes evident in Casr-deficient mice, as their
lethal phenotype normally observed after deletion of the
Casr gene can be rescued by crossing these mice with
mice deficient inPth. However, in these double-knockout
mice with a complete absence of circulating PTH, the
variance of serum Ca2+, as well as the fractional excretion
of Ca2+, exceeded the variance observed in Pth-deficient
mice with an intact CaSR [107]. These results suggest that
CaSR is important in regulating Ca2+ homoeostasis also
independently of regulating PTH secretion.
DCT, CNT (CONNECTING TUBULE) AND
INITIAL CDs
The distal convolutions are often defined as compris-
ing the DCT, CNT and the initial CD [108]. Several
species differences can be observed in the composition
and borders of the individual nephron segments,
particularly between rabbit compared with human, mice
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and rat. Although the transition between the different
nephron segments ends abruptly in the rabbit, the
borders between these segments are more intermingled
in the other species. Lumen negative transepithelial
voltage increases from approx. −5 mV in the early
convolutions up to approx. −40 mV or more towards
the end of the late convolutions [109–113]. However,
some variability in the measured voltages have been
reported [109]. Detailed micropuncture studies have
estimated that approx. 3–7 % of the filtered Ca2+ is
reclaimed between the early or late distal sites and the
final urine in the rat [10,19,114]. However, the absence
of direct determinations of delivery in juxtamedullary
nephrons may only provide approximate estimates. It
is unclear whether these punctures represent the whole
Ca2+-transporting segment in the distal convolutions.
Approx. 2 % of the filtered load is reabsorbed between
early and late distal collections in the same nephron,
whereas the amount doubles in the presence of PTH
[115]. Ca2+ reabsorption is essentially thought to be
active, as it occurs in the presence of lower intraluminal
Ca2+ concentrations and lumen negative transepithelial
voltages [10].
The TRPV5 [TRP (transient receptor potential)
vanilloid 5] channel provides the main apical entry
step for Ca2+ in the distal convolutions. TRPV5 was
originally cloned from primary cultures of rabbit renal
CNT/cortical CD tubules [116]. The channel localizes
primarily to the CNT in the rabbit [117,118]. In other
rodents, expression of TRPV5 is found in the DCT2
segment [expressing NCC (Na+–Cl− co-transporter) and
ENaC (epithelial Na+ channel)], the CNT and the ini-
tial CD [118–121]. The channel co-localizes with the
Ca2+-binding protein calbindin-D28K and the basolateral
extrusion proteins PMCA1b (plasma membrane ATPase
1b) and NCX1 (Na2+/Ca2+ exchanger type 1). Transgenic
mice lacking TRPV5 have augmented renal Ca2+
loss, and micropuncture studies effectively demonstrate
that Ca2+ reabsorption in the distal convolutions is
disturbed [122]. Several studies have shown TRPV5 as an
essential constituent in transcellular Ca2+ reabsorption
and it is, therefore, surprising that no monogenic
disorders or polymorphisms have been identified thus far
[123].
Detailed physiological measurements suggest that the
distal convolutions are responsible for reabsorbing 5–6 %
of the filtered Mg2+ [19,124]. Again, these values were
determined by subtracting the delivery of ions to the
distal sites and the final urine. Similar experiments have
reported that approx. 8 % of the filtered load is reabsor-
bed between the early and late distal collections [115].
Brunette et al. [124] suggested that, on the basis
of their early and late distal micropuncture results,
reabsorption of Mg2+ is localized in the early portion
rather than along the whole distal tubule, thus, predomin-
antly in the DCT. The early distal tubule constitutes
a high-resistance epithelium with a lumen negative
voltage of approx. −5 mV [55,110,111]. Moreover,
the transepithelial movement of Mg2+ appears to be
unidirectional. These observations support the presence
of active transcellular Mg2+ transport in this segment
[125]. This is corroborated further by the observation
that the luminal Mg2+ concentration in the DCT ranges
between 0.2 and 0.7 mmol/l [4], while that of the cell
is maintained approx. 0.2–1.0 mmol/l [126,127]. Under
these conditions, uptake of Mg2+ across the apical
membrane would be dictated largely by the negative
intracellular membrane potential found in the DCT
cell [128,129]. In addition, distal reabsorption of Mg2+
appears to be load-dependent, as increasing delivery
augments reabsorption [54,125]. Cellular influx of Mg2+
probably occurs through the TRPM6 (TRP melastin 6)
channel, a channel selective for divalent cations [130].
TRPM6 is structurally similar to other TRP channels
with six transmembrane segments. Only shared with
TRPM7 is the unique α-kinase domain fused to the
C-termini [131]. It is worth noting that the current debate
questions whether TRPM6 functions as a homo-tetramer.
Distinctive properties of functional homomeric TRPM6
channels, as well as TRPM6/TRPM7 heteromeric chan-
nels, have been recorded [132]. In addition, several groups
have reported the electrophysiological characteristics of
TRPM6 in mammalian cells without simultaneously
expressing TRPM7 [130,132,133]. In contrast with
these observations, others have reported that TRPM7
expression is necessary for localization at the plasma
membrane and for the generation of TRPM6 currents
[134–137]. Thus the exact molecular composition of the
Mg2+ influx pathway in transporting epithelia remains to
be determined. Trpm6 mRNA expression was restricted
to the kidney, lung and intestine (with the highest
abundance in colon and caecum of mice) [138,139].
Immunohistochemical localization of the channel has
been reported, where TRPM6 was restricted to the apical
membrane domains of renal DCT cells [130]. Intracellular
carrier proteins and basolateral excursion mechanisms are
yet to be identified.
TRANSPORT DEFECTS OF THE DCT
AFFECTING DIVALENT CATION HANDLING
HSH (hypomagnesaemia with secondary
hypocalcaemia)
TRPM6 was originally identified as the causative gene
of the autosomal-recessive disorder known as HSH
[139,140]. Individuals suffering from HSH present in
early infancy with symptoms related to neuromuscular
excitability, such as muscle spasms, tetany and generalized
convulsions [141]. These symptoms probably occur
as a consequence of a severe fall in plasma Mg2+
and Ca2+ concentrations. Symptoms can be reduced
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by high dose Mg2+ administration. Interestingly, this
Mg2+ supplementation normalizes the plasma Ca2+
concentration, while plasma Mg2+ remains subnormal
[142]. A patient with HSH had a failure to effectively
absorb Mg2+ from low intraluminal intestinal Mg2+
concentrations [143]; however, the patient with HSH
had a positive Ca2+ balance, excluding a common defect
in Mg2+ and Ca2+ transport mechanisms. These results
support a role for TRPM6 in saturable active Mg2+ trans-
port, serving as an apical entry mechanism for Mg2+ in
the enterocyte. Although the hypomagnesaemia in HSH
appears to be primarily the result of malabsorption of
Mg2+ in the intestine, there is also a serious, although
not well studied, renal Mg2+ leak. Patients with HSH
have been reported to have either normal renal Mg2+
conservation [142–144] or an additional renal Mg2+ leak
[139,140,145]. However, when an intravenous Mg2+ load
was administered to patients with HSH, renal wast-
ing was clearly noticeable [140]. Thus these individuals
waste urinary Mg2+ at a lower plasma concentration
than normal individuals do. Agus [146] has described
previously that maintaining a fractional Mg2+ excretion
above 2 % in the presence of hypomagnesaemia should
be considered a renal leak in itself. This is corroborated
by a report showing an inappropriately high fractional
excretion given severe hypomagnesaemia in patients with
HSH [139].
IRH (isolated autosomal-recessive
hypomagnesaemia)
This rare form of hypomagnesaemia was initially
described in two siblings who presented with low serum
Mg2+ concentrations and an inappropriately high frac-
tional excretion of Mg2+ [147]. In addition, these indivi-
duals suffered from psychomotor retardation during their
youth and are presently suffering from moderate mental
retardation and epileptic seizures [147,148]. Thus these
observations indicated a potential defect largely related to
renal Mg2+ transport, similar to that observed for Mg2+-
loaded patients with HSH. Interestingly, there were no
observable secondary changes in the handling of Ca2+
[147], which may to some extent explain why these
patients are devoid of tetany. Detailed homozygosity
mapping approaches and direct sequencing revealed that
these sisters had a mutation in theEGF (epidermal growth
factor) gene, causing a defect in the routing of the pro-
EGF to the basolateral plasma membrane [148]. This
mutation resulted in impaired autocrine/paracrine secre-
tion of EGF to the interstitium, thereby inhibiting the
activation of basolateral EGFRs (EGF receptors) in
the DCT. Subsequent patch–clamp analysis and classical
biochemical experiments showed that application of EGF
activates TRPM6 and shuttles it from endomembrane
compartments to the membrane [148,149]. Interestingly,
inhibition of the EGFR by cetuximab, a monoclonal
anticancer drug, causes pronounced hypomagnesaemia
in colorectal cancer patients [148,150]. Unlike patients
with impaired sorting of the EGF protein, cetuximab
treatment produces secondary hypocalcaemia in patients
with moderate-to-severe hypomagnesaemia (grade 2 or
higher), probably resulting from impaired PTH secretion
[150]. Similarly, patients with severe hypomagnesaemia
did show signs of fatigue and cramps. IRH and related
inhibition of the EGFR by cetuximab diverges from HSH
in several of the phenotypic characteristics, suggesting
perhaps additional effects of EGF on Mg2+ handling.
Incubation of TRPM6-expressing cells with cetuximab
completely abolishes the EGF-induced increases in
channel currents [149]. Unlike TRPM6, the current
literature suggests that TRPM7 is not activated by EGF
and thus appears to be an unlikely target [149]. Whether
other transporters are involved in conferring hypomag-
nesaemia in IRH remains to be defined. Taken together,
these results indicate that EGF is a novel magnesio-
tropic factor acting primarily to increase renal Mg2+
reabsorption.
Isolated dominant hypomagnesaemia
This form of hypomagnesaemia was characterized in two
unrelated families [151]. Affected individuals showed
isolated renal Mg2+ wasting, as the renal reabsorption
of Mg2+ remained within the normal range in the pres-
ence of hypomagnesaemia. The only other observable
renal symptom was a lowered excretion of Ca2+ in the
urine [151]. The underlying defect was later described
to be a G41R mutation in the FXYD2 gene, the so-
called Na+/K+-ATPase γ -subunit. FXYD proteins are
a family of single transmembrane proteins known to
modulate Na+/K+-ATPase function. The exact intrarenal
localization of the FXYD2 protein is controversial,
although some reports suggest that it localizes to the DCT
[152–155]. The FXYD2 protein changes the Na+/K+-
ATPase kinetics by reducing the affinity for Na+ while
increasing that for K+ [152,156,157]. FXYD2 G41R
proteins have been shown to oligomerize, similar to the
wild-type subunit. However, although FYXD2 localizes
to the cytoplasm and the plasma membrane, the G41R
mutant is retained in the cell. Thus it is suggested that
the dominant-negative FXYD2 G41R protein would
oligomerize with wild-type FXYD2 proteins, retaining
them inside the cell unable to bind and activate the other
Na+/K+-ATPase subunits [158,159]. Thus the current
hypothesis states that reducing outward basolateral
Na+ transport in the polarized DCT cell reduces the
intracellular voltage, thereby reducing the inward electric
driving force for Mg2+ potentially through TRPM6.
Interestingly, mice with a targeted disruption of the
Fxyd2 gene have no change in the urinary excretion of
Mg2+ or serum Mg2+ concentrations [154]. The absence
of hypomagnesaemia is also observed by heterozygous
deletion of the entire FXYD2 gene in humans, indicating
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that renal Mg2+ loss in this disease is due to a dominant-
negative nature of the G41R mutation, rather than
haploinsufficiency [158]. A recent report [160] suggests a
potential role for FXYD2 as an inward rectifying channel,
which differs from that of the FXYD2 G41R mutant.
Moreover, the authors speculate that the FXYD2 protein
can be involved in the basolateral extrusion of Mg2+
from the cell [160]. The exact role of the γ -subunit in
regulating renal Mg2+ reabsorption remains to be clarified
experimentally.
Gitelman’s syndrome
Gitelman’s syndrome is a salt-losing disorder char-
acterized by hypokalemic metabolic alkalosis, hypo-
magnesaemia and hypocalciuria [161]. Renin activity
and aldosterone concentrations are elevated, but only
marginally in comparison with patients with Bartter’s
syndrome. The disorder is autosomal-recessive and
is caused by mutations in SLC12A3, which encodes
the thiazide-sensitive NCC [162]. The Gitelman’s
phenotype is mimicked by chronic thiazide treatment,
a potent blocker of NCC [163,164]. The hypocalciuric
effect of SLC12A3 gene deletion or chronic thiazide
administration is probably due to hypovolaemia,
although some reports have suggested an additional direct
effect on Ca2+ reabsorption in the distal convolutions
[165,166]. Volume contraction causes secondary increases
in proximal tubular Na+ transport and, thus, facilitates
paracellular hyperabsorption of Ca2+. This is supported
by several observations. Micropuncture studies in mice
with genetic ablation of the Slc12a3 gene had a reduced
delivery of Na+ and Ca2+ to the late proximal tubule,
consistent with increased Na+ and Ca2+ reabsorption in
the proximal tubule. In addition, these micropuncture
experiments indicated that Ca2+ reabsorptive rates were
similar in the distal convolutions in the wild-type and
Slc12a3-deficient mice [167]. In wild-type mice admin-
istered thiazide diuretics, similar observations were
made using micropuncture studies, suggesting that the
hypocalciuric effect localizes to the proximal tubule [168].
Furthermore, thiazide-induced hypocalciuria can still be
observed in Trpv5-deficient mice, which effectively lack
Ca2+ transport in the distal convolutions [168]. This
satisfactorily confirms that the mechanism by which
hypocalciuria develops after thiazide usage and probably
also in Gitelman’s syndrome is independent of distal Ca2+
reabsorption.
Hypomagnesaemia is a consistent feature of Gitelman’s
syndrome. The phenotypic characteristic is likely to be
the result of a decreased abundance of TRPM6, leading
to renal Mg2+ wasting. However, the mechanism that de-
creases renal TRPM6 expression in Gitelman’s syndrome
remains incompletely understood. Mice deficient in
NCC, as well as rats given thiazides, have severe
atrophy of the DCT (i.e. the fractional volume of the
early DCT is drastically reduced) [167,169]. In addition,
Slc12a3-deficient mice have a decreased expression of
TRPM6, which localizes intrarenally solely within the
DCT [168]. Interestingly, in contrast with previous
results, administration of lower doses of thiazides
produce no changes in the morphology of the DCT,
while the expression of TRPM6 remains decreased [168].
Aldosteronism, a recurring feature of Gitelman’s syn-
drome, has been implicated in renal Mg2+ wasting [170–
172]. Similarly, a lack of aldosterone can be associated
with hypermagnesaemia [170,171]. Spironolactone, a
mineralocorticoid receptor antagonist, has been shown
to consistently reduce urinary Mg2+ excretion in a
number of patient groups [170,171,173]. In patients with
Gitelman’s syndrome, spironolactone treatment increases
serum Mg2+ concentrations and reduces the fractional
tubular excretion of Mg2+ [173]. Thus some studies have
suggested that the apparent aldosterone excess observed
in Gitelman’s syndrome may be an underlying cause.
Conversely, chronic infusion of aldosterone does not
change the renal mRNA abundance of Trpm6 in mice
[172]. Moreover, marked hyperaldosteronism is observed
in patients with antenatal Bartter’s syndrome, while less
than 20 % of these individuals display hypomagnesaemia.
The positive effect of spironolactone on Mg2+ balance
deserves further research. Currently, the absence of NCC
in DCT has been shown to induce hypocalciuria via
changes in proximal tubular reabsorption and hypo-
magnesaemia by reducing TRPM6 expression.
TRANSPORT DEFECTS OF THE DISTAL
CONVOLUTIONS AFFECTING DIVALENT
CATION HANDLING
dRTA (distal renal tubular acidosis)
Metabolic acidosis caused by an inability of the distal
tubule to effectively secrete H+ ions is referred to as
dRTA. dRTA and other types of metabolic acidosis
are often accompanied by hypokalaemia, hypercalciuria,
nephrocalcinosis and metabolic bone disease. dRTA can
be hereditary in an autosomal-dominant fashion or
occur as a rarer recessive form which may be asso-
ciated with sensorineural deafness. The underlying gene
defect of dominant dRTA is due to mutations in SLC4A1
[encoding band 3 erythrocyte AE1 (anion exchanger 1)]
[174], whereas mutations in ATP6V1B1 and ATP6V0A4
(encoding subunits of the proton pump H+-ATPase)
cause recessive dRTA with [175] or without [176]
sensorineural deafness respectively. It has long been
known that metabolic acidosis affects Ca2+ handling.
Persistent acidosis is buffered by alkaline salts released
from bone, thereby promoting Ca2+ release from the
hydroxyapatite crystal. These effects ultimately lead
to osteomalacia and osteoporosis and may promote
hypercalciuria [177]. Micropuncture experiments, show
that distal tubular Ca2+ reabsorption is inhibited by
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chronic metabolic acidosis [178], suggesting that renal
Ca2+ wasting is not merely due to Ca2+ mobilization
from bone, but also constitutes an additional renal
component. These findings are in good agreement with
the observation that the renal expression of TRPV5 is
decreased during experimental metabolic acidosis. In line
with this, renal Ca2+ excretion is refractory to NH4Cl-
induced metabolic acidosis in Trpv5-deficient mice [179].
Thus the effect of impaired distal secretion of protons and
other disturbances (such as renal failure, liver cirrhosis
etc.) that cause metabolic acidosis affects the renal tubular
transport of Ca2+. Interestingly, Ca2+ influx, probably
as the result of acute changes in subcellular distribution
and of single channel properties of TRPV5, is regulated
by the luminal pH, i.e. acidification of the medium
inhibits TRPV5-mediated Ca2+ reabsorption [180,181].
Thus, during conditions of increased distal tubular proton
secretion or delivery (metabolic acidosis due to causes
other than dRTA), these TRPV5-specific effects probably
also contribute to the observed hypercalciuria.
During dRTA, failure to effectively lower the
intraluminal pH in the CNT/CD causes metabolic
acidosis. During regular metabolic acidosis, urinary pH
becomes more acidic to compensate for the decreased
systemic pH; however, hypercalciuria is observed in
both conditions. As experimental metabolic acidosis
involves a renal component, this probably also occurs
in dRTA. This is supported by the observation that most
patients with an AE1 defect develop nephrocalcinosis,
while few show signs of bone disease (although minor
losses from bone could promote Ca2+ wasting) [174].
Furthermore, acetazolamide induces metabolic acidosis
by reducing proximal tubule HCO3− reabsorption and,
hence, increasing urinary pH, a situation similar to dRTA
[182]. However, as observed with NH4Cl treatment,
acetazolamide administration causes the down-regulation
of TRPV5 in mice, and the hypercalciuria associated
with acetazolamide-induced acidosis is absent in
Trpv5-deficient mice. Hence changes in systemic pH
probably promote the down-regulation of renal TRPV5
expression. In contrast, chronic metabolic alkalosis is
associated with increased Ca2+ reabsorption and TRPV5
abundance. However, the Ca2+-sparing effect is also
observed inTrpv5-deficient mice, suggesting that another
unknown mechanism is responsible for the increased
Ca2+ reabsorption [179].
In patients with dRTA, serum Mg2+ concentrations
remains unaffected [174,183]; however, children with
dRTA present with hypermagnesuria, which can be cor-
rected by HCO3− administration [183]. Detailed clear-
ance and micropuncture studies have shown that chronic
metabolic acidosis causes hypermagnesuria beyond the
proximal tubule [184]. Furthermore, chronic metabolic
acidosis decreases the renal abundance of TRPM6,
whereas metabolic alkalosis has the opposite effect [179].
Acidic pH also augments the inward current of TRPM6,
suggesting that perhaps acute changes in intraluminal
pH may affect the channel in an opposite manner
from chronic metabolic acidosis. The physiology of this
observation is still incompletely understood [132].
PHAII (pseudohypoaldosteronism type II)
The WNK (with-no-lysine) kinase family consists of
serine/threonine kinases with a characteristic displace-
ment of a catalytic lysine residue necessary for ATP
binding [185,186]. The identification of the WNK
family members as multifunctional proteins required for
ambient BP maintenance and renal electrolyte handling
has progressively broadened the knowledge of how
these processes are regulated [187,188]. PHAII, also
known as Gordon’s syndrome, is an autosomal-dominant
disorder associated with hypertension, an augmented
renal reabsorption of Na+/Cl− and impaired secretion
of K+ and H+ [188,189]. The genetic defects in PHAII
are due to loss-of-function mutations in WNK4, as well
as activating mutations in WNK1 caused by intronic
deletions [188]. Several studies have now shown that
WNK1 and WNK4 play important roles in modulating
electrolyte transport pathways in the distal convolutions
[190–193].
In addition to the often hypertensive phenotype,
hypercalciuria and nephrolithiasis has been reported in
patients with PHAII [194,195]. Accordingly, individuals
carrying a WNK4 Q565E mutation present with
hypercalciuria and a decreased bone mineral density.
Conversely, affected members with activating WNK1
mutations present with normocalciuria [196]. It is
interesting to note that no apparent change is observed
in serum Mg2+ concentrations or renal Mg2+ handl-
ing in patients with PHAII [196–198]. The mechanism
by which dysfunctional WNK4 stimulates calciuria in
PHAII is unclear, but may occur via several mechanisms.
(i) Secondary to volume expansion, a condition that is
predicted to reduce proximal tubule Na+ reabsorption,
resulting in decreased electrochemical driving force
for Ca2+ uptake across the proximal tubular epithelia
[16,168,199]. As the majority of Ca2+ reabsorption
occurs in the proximal tubule, volume expansion might
be the largest contributor to hypercalciuria in PHAII.
Even so, individuals carrying the WNK1 deletion have
normocalciuria in the presence of elevated BP (and
probably an expanded extracellular volume). (ii) Alter-
natively, the hypercalciuric phenotype in PHAII may
be due to impaired interactions between WNK4 and
renal Ca2+ transport proteins [200]. In line with this, it
has been reported that WNK4 directly activates Ca2+
transport by increasing the surface expression of TRPV5
in theXenopus oocyte expression system [200]. However,
the WNK4 PHAII mutants showed a similar activating
effect on TRPV5. Using lentivirus-induced gene delivery
to primary rabbit CNT/cortical CD cells, we found
that cells infected with WNK4 and the WNK4 Q565E
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mutant both decreased transepithelial Ca2+ transport (H.
Dimke, J.G. Hoenderop and R.J. Bindels, unpublished
work). Consequently, the exact aetiology underlying
hypercalcaemia in PHAII needs further clarification. It
is interesting to note that, although PHAII is considered
a mirror image of Gitelman’s syndrome, no changes in
serum Mg2+ have been observed in these individuals.
COLLECTING SYSTEM
It is generally accepted that the CD does not contri-
bute significantly to overall renal Ca2+ transport.
Classical micropuncture studies have been aided by
determining the fraction of Ca2+ transport after the distal
convolutions, by allowing late distal measurements of
cations. On the basis of the observations that (i) relatively
little K+ secretion is thought to occur in the early distal
convolutions comprising the DCT and (ii) K+ secretion
coupled with increased osmotic water permeability in
CNT and accessible CD segments markedly raises
luminal K+ concentration, it was possible to correlate
the fractional delivery of Ca2+ to the luminal K+
concentration at distal puncture sites. As evident from the
intrarenal distribution of TRPV5, Ca2+ delivery decreases
with increased luminal K+ concentration in wild-type
mice. Conversely, in mice with a targeted disruption of
the Trpv5 gene, Ca2+ delivery was markedly increased
with increasing luminal K+ concentrations [122]. Results
obtained from these experiments and others suggest that
very little Ca2+ (<2 %) is delivered to segments of
high K+ secretion [122,168]. Assuming that the highest
luminal K+ concentration represents the very latest
superficial distal convolutions, negligible Ca2+ transport
must occur in the remainder of the CD. Microperfusion
of the granular and light portions of the cortical ducts
in the rabbit have suggested that Ca2+ transport only
occurs in the granular portion. Thus the non-superficial
segments of the collecting system probably provide a
small contribution to overall renal Ca2+ reabsorption.
The relative contributions of the CD to overall Mg2+
reabsorption are probably negligible. Estimations from
micropuncture studies suggest little Mg2+ transport after
the DCT. Microperfusion of cortical CDs failed to show
a significant amount of net Mg2+ movement [201]. In line
with this, microcatheterization studies found no net Mg2+
transport over the length of the inner medulla CD [202].
HYPOMAGNESAEMIA, HYPERTENSION AND
HYPERCHOLESTEROLAEMIA
A large family was identified with a high prevalence
of hypomagnesaemia, hypertension, and hypercholester-
olaemia [203]. Interestingly, males with the syndrome
did not transmit the phenotype to their offspring.
Conversely, offspring from affected females inherited
the trait with high frequency, suggesting mitochondrial
transmission. The defect was discovered to be a thy-
midine-to-cytidine conversion near the anticodon of
the isoleucine tRNA. Subjects suffering from hypomag-
nesaemia had an augmented fractional excretion of Mg2+,
indicative of renal wasting. Individuals in the maternal
lineage also had renal Ca2+ loss. Hypokalaemia was
present in subjects with hypomagnesaemia, perhaps as
a consequence of hypomagnesaemia. In one affected
member, immunohistochemical and electron microscopic
evaluation revealed signs of mitochondrial dysfunction.
In line with this, NMR revealed a decreased production
of ATP in skeletal muscle [203].
The exact aetiology underlying this disorder remains
unclear. The authors suggested that reduced energy
production could limit the highly energy consuming
DCT and thereby impede transcellular Mg2+ transport
[109]. How large a reduction would be needed to
diminish the membrane potential enough to affect Mg2+
reabsorption in the DCT is unclear; however, the renal
Na+ excretion remained unchanged between the affected
and unaffected family members [203].
SUMMARY
The necessity of maintaining the systemic concentrations
of Ca2+ and Mg2+ within normal limits is evident, as
disturbances in these divalent cations affect important
physiological processes. For instance, hypomagnesaemia
is a recurrent condition often encountered in the clinical
setting. The detailed characterization of the underly-
ing causes of monogenic diseases related to defective
renal Ca2+ and Mg2+ handling has greatly aided the
understanding of how renal and, hence, systemic divalent
homoeostasis is maintained. Proximal tubular transport
defects, such as Dent’s disease, can cause hypercalciuria.
In the TAL, inadequate, absent or even increased ion
transport confers several syndromes, which drastically
changes the renal handling of Ca2+ and Mg2+. In addition,
vectorial transcellular Ca2+ and Mg2+ transport in the
distal convolutions can be disturbed as a consequence
of changes in the transport of other ions or by directly
affecting TRP channel function. An even better under-
standing of the mechanisms governing the transport of
Ca2+ and Mg2+ can be obtained by studying these disease
conditions or by mimicking these in genetically modified
animals.
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